Research programme: monoclonal antibody therapeutics - Curacyte

Drug Profile

Research programme: monoclonal antibody therapeutics - Curacyte

Alternative Names: VTR 4

Latest Information Update: 26 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scottish National Blood Transfusion Service
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Systemic inflammatory response syndrome

Most Recent Events

  • 10 Jun 2002 VitaResc Biotech has been acquired by, and merged into, Curacyte AG
  • 03 Nov 1999 Preclinical development for Systemic inflammatory response syndrome in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top